(TX_TB) The proportion of ART patients who were screened who are receiving TB treatment.

Export Indicator

The proportion of ART patients who were screened who are receiving TB treatment.
What it measures

This indicator documents the TB screening of ART patients as well as the proportion who were diagnosed and started on TB therapy. The disaggregates demonstrate the cascade from screening to testing

Numerator

The number of ART patients who were started on TB treatment during the reporting period.

Denominator

The number of ART patients who were screened for TB at least once during the reporting period.

Calculation

Sum numerator across both reporting periods.

Method of measurement

The denominator can be generated by counting the number of ART patients who were screened for TB symptoms at least once during the reporting period. This includes newly enrolling patients as well as patients currently on ART.

The numerator can be generated by counting the number of those patients who were diagnosed with TB and started on TB therapy during the reporting period. These data should be captured in ART registers as well as additional data collection sources (i.e., facility-based TB screening registers or forms, TB specimen registers, TB microscopy result registers, GeneXpert data collection systems) that may contain relevant information (i.e., TB screening results, TB specimen testing results). Programs should modify the register as needed to easily capture this information.

* Screening for TB and/or initiation of TB therapy might not happen at the same time that ART is started. Regardless of when they occur relative to ART initiation, TB screening and initiation of TB therapy should be included for all patients who are currently on ART or who started ART at any time during the reporting period.

How to review for data quality:

Only one disaggregation type is used for age (coarse disaggregates). Numerator ≥ subtotal of each of the disaggregations.

 

Measurement frequency

Report 6 months of results at Q2/SAPR and Q4/APR. Ensure that each PLHIV is counted only once during the reporting period.

Disaggregation

Numerator:

The number of ART patients who were started on TB treatment during the reporting period.

Current on ART /New on ART

Age/Sex (Coarse Disaggregate)

Disaggregates and Description

1. The number of patients starting TB treatment who newly started ART during the reporting period

2. The number of patients starting TB treatment who were already on ART prior to the start of the reporting period

<15 F, 15+ F, <15 M, 15+ M

Denominator:

The number of ART patients who were screened for TB during the reporting period

Screen Result (Positive, Negative)

Specimen Sent

[Disagg of Specimen Sent] Diagnostic Test

Age/Sex (Coarse Disaggregate)

Disaggregates and Description

1. Positive: The number of ART patients who had at least one positive screen during the reporting period.

2. Negative: The number of ART patients who had all negative screens during the reporting period.

 Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease.

1. GeneXpert MTB/RIF assay (with or without other testing)

2. Smear microscopy only

3. Additional test other than GeneXpert

<15 F, 15+ F, <15 M, 15+ M

For DSD for HIV-related services, the provision of key staff and/or commodities can include ongoing provision of critical re-occurring costs or commodities (such as laboratory supplies, GeneXpert cartridges etc) and/or delivery of TB symptom screening and bacteriological testing to the counted individuals, such as through funding of salaries or provision of Health Care Workers for TB services. Staff responsible for maintaining patient records are included in this category however staff responsible for fulfilling reporting and routine M&E requirements are not included.

For DSD and TA for TB/HIV-related services, TB and HIV clinical care facilities and communitybased services will be counted as supported by TA/QI whenPEPFAR provides established presence and/or routinized, frequent (at least quarterly) support for the services by PEPFAR at the point of service delivery, clinical mentoring and supportive supervision of staff providing TB/HIV services, Quality Improvement services, routine support of M&E, TB screening and bacteriologic testing, commodities consumption forecasting and supply management, or specimen transport and result return.

Further information

MER 1.0 to 2.0 Change

This indicator is new, and incorporates elements of TB_SCREEN and TB_ART; as such, there is no direct comparator from MER 1.0